The MHRA has published its annual report and accounts for the 2023 to 2024 financial year, revealing that the organisation grew its headcount but missed targets.
The latest report puts MHRA’s headcount at 1,416, up from 1,285 the previous year. However, MHRA continued to miss targets, and its performance deteriorated in some areas. The agency met its target for 25% of new active substances assessed via the national route, down from an 88% on-time rate in the previous year. MHRA aims to hit its target 97% of the time.
MHRA assessed 40% of clinical trial applications within 30 days of submission. The figure is up on the 25.9% rate of on-time assessments in the previous year but down on the 98% targeted by the agency.
BIVDA recognises that the MHRA is undergoing a period of transformation, which should yield results in time. The MHRA remains a key stakeholder and we look forward to continuing our close relationship for the benefit of members.
The report can be found here.
